阿尔茨海默病(AD)是一种以进行性痴呆为表现的神经变性病。65～69岁患病率约1%,85岁以上患病率将近20%[1]。目前中国的AD患病率4.8%[2]。盐酸多奈哌齐(商品名:安理申)作为胆碱酯酶抑制剂,被公认为是治疗轻、中度AD“金标准”药物。2008年1月—2010年2月,我们采用盐酸多奈哌齐对照试验评估肉苁蓉总苷治疗轻、中度AD的有效性和安全性,现 Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive dementia. The prevalence of 65 to 69 years old is about 1%, and the prevalence of over 85 years old is nearly 20% [1]. At present, the prevalence of AD in China is 4.8% [2]. As a cholinesterase inhibitor, donepezil hydrochloride (trade name: Aricept) is recognized as a treatment for mild to moderate AD “gold standard”. From January 2008 to February 2010, we evaluated the efficacy and safety of glycosides of cistanche in the treatment of mild and moderate AD using the donepezil hydrochloride controlled trial